Spontaneous remission of advanced progressive poorly differentiated non-small cell lung cancer: a case report and review of literature

Hee-Young Yoon, Heae Surng Park, Min Sun Cho, Sung Shin Shim, Yookyung Kim and Jin Hwa Lee

Abstract

Background: Spontaneous remission (SR) of cancer is a very rare phenomenon of unknown mechanism. In particular, SR of non-small cell lung cancer (NSCLC) has been scarcely reported. We present the case of a 74-year-old woman with advanced, poorly differentiated NSCLC (highly expressing programmed death ligand-1 [PD-L1]) that progressed despite multiple lines of chemotherapy but then spontaneously remitted.

CASE presentation: The patient presented with hemoptysis and was diagnosed with stage IIIA poorly differentiated NSCLC via bronchoscopic biopsy. She had an unremarkable medical history and moderate performance status. The initial treatment plan was surgery after neoadjuvant chemotherapy. Despite conventional chemotherapy, follow-up chest computed tomography (CT) showed gradual tumor progression and she decided against further treatment after fifth-line chemotherapy. However, the size of lung mass was markedly decreased on follow-up chest CT one year after ceasing chemotherapy. Also, follow-up positron emission tomography images showed decreased metabolic activity in the lung mass and a percutaneous biopsy specimen from the diminished lung mass revealed no viable tumor cells. A diagnosis of SR of NSCLC was confirmed, and the patient was without tumor progression on follow-up nine months later. PD-L1 immunostaining revealed high positivity (> 99%) in initial tumor cells.

Conclusion: Our case showing SR of poorly advanced NSCLC refractory to multiple lines of chemotherapy suggested the association between immunity and tumor regression.

Keywords: Advanced stage, Chemotherapy, Prognosis, Immunity, Disease progression
Laboratory testing revealed no abnormal results except for mild elevation of C-reactive protein (0.44 mg/dL, reference: 0–0.3 mg/dL). Initial chest x-ray and computed tomography (CT) scan revealed a 5.1 × 2.9 cm lung mass in the left upper lobe with a surrounding halo of ground-glass attenuation (Fig. 1-a and b). There were also tiny lung nodules in the right upper and lower lobes that could not be ruled-out for malignancy and left hilar lymph node enlargement (11 L). Positron emission tomography/computed tomography (PET/CT) images showed a left lung mass with increased metabolic uptake (Figs. 2-a and b).

Diagnostic bronchoscopy revealed a polypoid mass with luminal obstruction of the left lingular inferior segmental bronchus (Fig. 3-a). Bronchoscopic biopsy of the lung mass was performed without complication. Histologic examination of an initial bronchoscopic biopsy showed poorly differentiated carcinoma with many tumor infiltrating lymphocytes (Fig. 4a). Immunohistochemical stains including cytokeratin (CK)-7, CK-20, thyroid transcription factor-1, napsin A, p63, p40 and CD56 were all negative. The initial pathological diagnosis was non-small cell carcinoma, not otherwise specified. The tumor was epidermal growth factor receptor wild type. An assay for anaplastic large-cell lymphoma kinase (ALK) rearrangement was not performed because the ALK inhibitor was not available. The patient was diagnosed with lung cancer in January 2015, long before the ALK inhibitor was approved for the treatment of lung cancer. Retrospective programmed death-ligand 1 (PD-L1) immunostaining (Ventana PD-L1 SP263 assay, Roche Diagnostics, Switzerland) showed high PD-L1 expression with a tumor proportion score of 99% (Fig. 4b).

After brain magnetic resonance imaging for cancer staging, which revealed a non-metastatic lesion, a tentative diagnosis of lung cancer with T3N1M0 (stage IIIA according to TNM seventh edition) was proposed. At first, the patient planned to undergo surgery after two cycles of paclitaxel plus carboplatin as neoadjuvant chemotherapy, inducing a decrease in the size of the lung mass from 5.1 × 2.9 cm to 4.1 × 1.5 cm. However, the patient developed drug-induced hepatitis with aspartate aminotransferase (AST) / alanine aminotransferase (ALT) of 110 / 182 IU/L due to a self-prescribed herbal medication, and the surgery schedule was delayed. For two weeks, waiting for the AST / ALT levels to drop, the lung mass slightly increased (4.1 × 2.6 cm), and she hesitated to undergo surgery. So afterwards she received additional two cycles of paclitaxel plus carboplatin, which means that she received a total of four cycles of paclitaxel plus carboplatin. However, the tumor still progressed, and fifth-line chemotherapy was sequentially...
administered until the fifth-line as follows: second-line for 4 cycles of gemcitabine plus carboplatin, third-line for 2 cycles of pemetrexed, fourth-line for 4 cycles of weekly docetaxel, fifth-line for 1 cycle of weekly vinorelbine. After a vinorelbine monotherapy, the patient refused further chemotherapy due to general weakness. At 4 months after discontinuation of chemotherapy, the size of the tumor on follow-up chest x-ray (Fig. 1-c) and CT (Fig. 1-d) was markedly increased (6.8 × 6.0 cm), directly invading left main pulmonary artery, left atrium, and left lower lobe. Thus, the patient again started irinotecan plus carboplatin as sixth-line chemotherapy. Although

Fig. 2 Comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography images before and after spontaneous remission of the left lung mass. a and b: A coronal positron emission tomography (PET) image in January 2015 revealed a mass with intense uptake (arrowhead) in the left lung (a) corresponding to a soft tissue density in a combined PET and CT fusion image (arrow). c and d: After the spontaneous remission, decreases in both size and uptake of the left lung mass were identified on a coronal PET image (c) and a combined PET and CT fusion image (arrow) (d) in October 2018.

Fig. 3 Comparison of bronchoscopic findings at the time of diagnosis of lung cancer and after spontaneous remission. a: On initial bronchoscopy, a polypoid endobronchial mass almost completely blocked the bronchial orifice of the lingular segment. b: After the spontaneous tumor remission, the entrance of the bronchus was replaced with a cicatricial lesion.
tumor size decreased after 4 cycles of chemotherapy, she decided to stop chemotherapy due to poor general condition and drug side effects and was scheduled for regular follow-up for tumor surveillance.

One year after discontinuation of treatment, a chest x-ray showed that the lung mass had decreased in size (Fig. 1-e). The patient had been taking herbal medication (Orostachys japonicus extracts) over the preceding few months. Chest CT taken during admission for disease status re-evaluation revealed the lung mass in the left lingular segment to have decreased in size to 3.6 × 2.5 cm (Fig. 1-f). PET/CT also demonstrated decreased size and metabolic activity of the lung mass (Figs. 2-c and d) and hilar lymph node. For further treatment planning, we performed bronchoscopy and intended repeat tumor biopsy, but only found fibrotic scar blocking the ligular segment instead of an endobronchial mass (Fig. 3-b). Histologic examination of the second bronchoscopic biopsy revealed chronic inflammation with foamy histiocytic infiltration (Fig. 4c). We subsequently conducted fluoroscopy-guided lung biopsy of the left lung mass. Percutaneous needle biopsy of the left lung lesion showed marked deposition of collagen and elastic fibers without tumor cells. (Fig. 4d). The histopathologic findings of second bronchoscopic biopsy and percutaneous lung needle biopsy were suggestive of tumor regression.

A diagnosis of SR of NSCLC was made, and the patient was without cancer progression on outpatient clinic follow-up at 9 months after the detection of SR.

Discussion and conclusion
Our patient experienced SR of PD-L1-positive, poorly differentiated, advanced NSCLC refractory to conventional chemotherapy. SR of cancer is a unique phenomenon and few studies on SR are available. SR of cancer is estimated to occur in one in every 60,000 to 100,000 cancer patients according to the type of cancer [2, 20]. A review of the literature by Challis and Stam, including 741 SR cases between 1900 and 1987, documented that nine types of cancer (kidney, neuroblastoma, melanoma, choriocarcinoma, bladder, retinoblastoma, lymphoma, leukemia, and breast cancer) accounted for 69% of all SR cases, while SR of lung cancer only occurred in 2.6% of all patients with SR [20]. Because of the very rare occurrence of SR in lung cancer, only a few biopsy-confirmed NSCLC SR cases have been reported (Table 1).

The mechanism of SR remains unclear. Interestingly, poorly differentiated cancer is common among the reported cases of SR in patients with NSCLC. Light microscopy alone may be insufficient to diagnose poorly differentiated carcinoma, which has been reported to
have a poor prognosis [21, 22]. The diagnosis of poorly differentiated carcinoma depends substantially on additional pathologist’s interpretation and adequate specimen size. The finding that many SR cases involved tumors showing poorly differentiated features despite testing with recently developed novel immunochemical markers suggests that the cancers of origin might have been misclassified. In addition, poorly differentiated NCLC has higher fluorodeoxyglucose (FDG) uptake at positron emission tomography and Ki-67 proliferation index compared with well-differentiated NSCLC [23].

Unlike most other reported SR cases, which involved smokers, our patient was a non-smoker. Several studies recently reported superior efficacy of immunotherapy in smokers compared with non-smokers but did not clarify the mechanism of this effect [31]. Also, strong PD-L1 positivity and presence of tumor infiltrating lymphocytes (TIL), which are predictive biomarkers for immunotherapy [32], were identified in this case. Taken together, our findings and the results of previous studies support the association between immunity and cancer control.

Our patient was taking herbal medication (Orostachys japonicus extracts) after the discontinuation of Table 1 Literature review of spontaneous remission of histologically confirmed non-small cell lung cancer

| Reference               | Age/Sex | Cell type | Stage | Smoking | Comorbidities | Treatment                                      |
|-------------------------|---------|-----------|-------|---------|---------------|-----------------------------------------------|
| Present study           | 74/F    | NSCLC, P/D| III   | None    | None          | Herbal remedy after ceasing multiple line chemotherapy |
| Matsui et al. 2018 [11] | 56/F    | SqCC, M/D | III   | Smoker  | CTD-ILD and autoimmune hepatitis          | None                                      |
| Ooi et al. 2018 [16]    | 77/M    | NSCLC, P/D| III   | None    | None          | None                                          |
| Marques et al. 2017 [10]| 75/M    | AC, NA   | I     | Smoker  | COPD, heart failure                      | None                                          |
| Park et al. 2016 [17]   | 79/M    | SqCC, NA | IV    | NA      | Hypertension, diabetes                    | None                                          |
| Chung et al. 2015 [5]   | 67/M    | SqCC, NA | IV    | NA      | None                                      | Chemotherapy and herbal remedy               |
| Ogawa et al. 2015 [15]  | 65/M    | NSCLC, P/D| IV    | Smoker  | none                                      | Radiotherapy                                 |
| Menon et al. 2015 [12]  | 44/M    | NSCLC, P/D| IV    | Smoker  | HIV                                      | None except HAART on combined HIV infection |
| Lopez-Pastorini et al. 2015 [9] | 76/M | LC, P/D | III   | Smoker  | hypertension                                 | None                                          |
| Hwang et al. 2013 [8]   | 62/M    | NSCLC, P/D| III   | Smoker  | IPF, diabetes                             | None                                          |
| Mizuno et al. 2011 [13] | 62/M    | LC, NA   | IV    | NA      | None                                      | None after surgery for initially stage I lung cancer |
| Furukawa et al. 2011 [6] | 56/M    | SqCC, NA | I     | Smoker  | COPD                                     | None                                          |
| Gladwish et al. 2010 [7] | 81/F    | SqCC, M/D| III   | Smoker  | Hypothyroidism                             | Herbal remedy (Essiac tea)                  |
| Nakamura et al. 2009 [14]| 71/M    | AC, P/D  | III   | NA      | Anti-NY-ESO-1 immunity disease            | None                                          |
| Pujol et al. 2007 [18]  | 75/F    | SqCC, NA | I     | Smoker  | Anti-Hu antibody syndrome, diabetes       | None                                          |
| Cafferata et al. 2004 [4] | 68/M    | AC, P/D  | I     | Smoker  | COPD, ischemic heart disease             | None                                          |
| Kappauf et al. 1997 [3] | 61/M    | LC, P/D  | IV    | NA      | None                                      | None                                          |
| Sperduto et al. 1988 [19] | 61/M    | SqCC, NA | IV    | Smoker  | COPD, basal cell cancer                   | None                                          |

AC: Adenocarcinoma, COPD: Chronic obstructive pulmonary disease, CTD-ILD: Connective tissue disease-related interstitial lung disease, F: Female; HAART: Highly active antiretroviral therapy, HIV: Human immunodeficiency virus, IPF: Idiopathic pulmonary fibrosis, LC: Large cell carcinoma, M: Male, M/D: Moderate differentiation, NA: Not applicable, SqCC: Squamous cell carcinoma, P/D: Poor differentiation.
chemotherapy. Gladwish et al. reported the case of a patient with SR of stable IIB NSCLC after receiving an herbal remedy (essiac tea) [7], which shows an antiproliferative effect on cancer cells at high concentration in vitro [33]. Chung et al. also reported the case of a patient with SR of NSCLC who took herbal medication during and after chemotherapy [5]. Orostachys japonicus is a flowering plant, containing several organic solvents including ethyl acetate with anti-cancer effects on human gastric cancer cells [34]. An in vivo model study also suggests the role of Orostachys japonicus in enhancing immunity by increasing immune cell propagation and production of immunity-related cytokines [35]. In our case, the tumor had many TIL and high PD-L1 expression, indicating that the patient had an antitumor immune response and had been eligible for treatment with an immune checkpoint inhibitor. Although no data are available to demonstrate the efficacy of Orostachys japonicus in humans, SR in our cases might be influenced by Orostachys japonicus intake.

Because our patient had received multiple cycles of chemotherapy before the occurrence of SR, there was a possibility of pseudo-progression or delayed response to chemotherapy. However, the chemotherapy regimen had changed several times, and tumor regression was observed one year after the last treatment, suggesting a high probability of SR. In addition, all of the chemotherapeutic agents administered to our patient would be less likely to show pseudo-progression because they are conventional drugs rather than immune checkpoint inhibitors.

In conclusion, we document a case of SR in a patient with advanced NSCLC refractory to conventional chemotherapy. Although the precise mechanism of SR in this case is unknown, the alteration of immunity might be an explanation. A single case cannot lead to a definite conclusion; nevertheless, our case indicates the importance of immunity in lung cancer control. Further well-designed animal model studies are needed to explore these findings.

Acknowledgments
Not applicable.

Authors’ contributions
J.H.L. had the conception of the work. H.Y.Y. drafted the manuscript. J.H.L., substantively revised it. Y.K.K. and S.S.S interpreted radiological findings and H.S.P. and M.S.C interpreted pathological findings. All authors approved the submitted version and agreed both to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

Funding
The corresponding author, J.H.L. received National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2010–0027945) for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials
Any data generated and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Not Applicable.

Consent for publication
A written informed consent was obtained from the patient for publication of this report and any accompanying images.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, 25 Magokdong-ro 2-gil Gangseo-gu, Seoul 07804, Republic of Korea.
2. Department of Pathology, College of Medicine, Ewha Womans University, 25 Magokdong-ro 2-gil Gangseo-gu, Seoul 07804, Republic of Korea.
3. Department of Radiology, College of Medicine, Ewha Womans University, 25 Magokdong-ro 2-gil Gangseo-gu, Seoul 07804, Republic of Korea.
4. National Cancer Center, Seoul, 25 Magokdong-ro 2-gil Gangseo-gu, Seoul 07804, Republic of Korea.

Received: 3 July 2019 Accepted: 31 October 2019
Published online: 11 November 2019

References
1. Cole WH, Eversen TC. Spontaneous regression of cancer: preliminary report. Ann Surg. 1956;144(3):366–83.
2. Cole WH. Efforts to explain spontaneous regression of cancer. J Surg Oncol. 1981;17(3):201–9.
3. Büschel G, Kaiser G, Kappe G, Mittelmeier H-O, Birkmann J, Kraus J, Wünsch PH, Gallmeier WM. Complete spontaneous remission in a patient with metastatic non-small-cell lung cancer: case report, review of literature, and discussion of possible biological pathways involved. Ann Oncol. 1997; 8(10):1031–9.
4. Cafferata MA, Chiaramondia M, Monetti F, Arzidoni A. Complete spontaneous remission of non-small-cell lung cancer: a case report. Lung cancer (Amsterdam, Netherlands) 2004, 45(2):263–266.
5. Chung C, Park DI, Kim SY, Kim JO, Jung SS, Park HS, Moon JY, Kim SM, Cho MJ, Jung SO, et al. Spontaneous regression of non-small cell lung cancer that progressed after multiple chemotherapies: a case report. Thoracic cancer. 2015;6(6):805–7.
6. Furukawa M, Otomo T, Yamane M, Toyooka S, Kiura K, Miyoshi S. Spontaneous regression of primary lung cancer arising from an emphysematous bulla. Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia. 2011;17(6):577–9.
7. Gladwish A, Clarke K, Bezjak A. Spontaneous regression in advanced non-small cell lung cancer. BMJ case reports 2010, 2010bcr0720103147.
8. Hwang ED, Kim YJ, Leem AY, Ji A-Y, Choi Y, Jung JY, Kim SK, Chang J, Park JH, Park SC. Spontaneous regression of non-small cell lung cancer in a patient with idiopathic pulmonary fibrosis: a case report. Tuberculosis and respiratory diseases. 2013;75(5):214–7.
9. Lopez-Pastorini A, Pilones T, Brockmann M, Ludwig C, Beckers F, Stoelben E. Spontaneous regression of non-small cell lung cancer after biopsy of a mediastinal lymph node metastasis: a case report. J Med Case Rep. 2015;9:217.
10. Marques C, Queiroga H, Marques M, Moura C. Spontaneous regression of a pulmonary adenocarcinoma after core needle biopsy. Autopsy & case reports. 2017;7(3):20–5.

Abbreviations
CK: Cytokeratin; CT: Computed tomography; FDG: Fluorodeoxyglucose; NSCLC: Non-small cell lung cancer; PD-L1: Programmed death ligand-1; PET/CT: Positron emission tomography/computed tomography; SR: Spontaneous remission

Acknowledgments
Not applicable.
Yu H, Boyle TA, Zhou C, Rimm DL, Hirsch FR. PD-L1 expression in lung cancer. 2018; 9(2):1778–81.

Mention MP, Eaton KD. Spontaneous Regression of Non–Small-Cell Lung Cancer in AIDS After Immune Reconstitution. J Thorac Oncol 2015; 10(1):e1–e2.

Mizuno T, Usami N, Okasaka T, Kawaguchi K, Okagawa T, Yokoi K. Complete spontaneous regression of non-small cell lung cancer followed by adrenal relapse. Chest. 2011;140(2):527–8.

Nakamura Y, Noguchi Y, Satoh E, Uenaka A, Sato S, Kitazaki T, Kanda T, Soda H, Nakayama E, Kohno S. Spontaneous remission of a non-small cell lung cancer possibly caused by anti-NY-ESO-1 immunity. Lung cancer (Amsterdam, Netherlands) 2009, 65(1):119–122.

Ogawa R, Watanabe H, Yazaki K, Fujita K, Tsunoda Y, Nakazawa K, Homma S, Mizuno T, Usami N, Okasaka T, Kawaguchi K, Okagawa T, Yokoi K. Complete spontaneous regression of non-small cell lung cancer with spontaneous regression of primary and metastatic sites: a case report. Oncol Lett. 2015;10(1):550–2.

Ooi KH, Cheo T, Soon GST, Leong CN: Spontaneous regression of locally advanced nonsmall cell lung cancer: A case report. Medicine 2018, 97(31).

Park YH, Park BM, Park SY, Choi JW, Kim SY, Kim JO, Jung SS, Park HS, Moon JY, Lee JE. Spontaneous regression in advanced squamous cell lung carcinoma. Journal of thoracic disease. 2016;8(3):E235–9.

Pujol JL, Godard AL, Jacot W, Labauge P. Spontaneous complete remission of a non-small cell lung cancer associated with anti-Hu antibody syndrome. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2007;2(2):169–70.

Sperduto P, Vaezy A, Bridgman A, Wilke L. Spontaneous regression of squamous cell lung carcinoma with adrenal metastasis. Chest. 1988; 94(4):887–9.

Challis GB, Stam HJ: The spontaneous regression of cancer. A review of cases from 1900 to 1987. Acta oncologica (Stockholm, Sweden) 1990, 29(5): 545–550.

Sun Z, Aubry MC, Deschamps C, Marks RS, Okuno SH, Williams BA, Sugimura H, Pankratz VS, Yang P. Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases. J Thorac Cardiovasc Surg. 2006;131(5): 1014–20.

Chung CK, Zaino R, Stryker JA, O’Neill M Jr, DeMuth WE Jr. Carcinoma of the lung: evaluation of histological grade and factors influencing prognosis. Ann Thorac Surg. 1982;33(6):599–604.

Vesselle H, Salskov A, Turcotte E, Wiens L, Schmidt R, Jordan CD, Vallières E, Wood DE. Relationship between non-small cell lung Cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index. J Thorac Oncol. 2008; 3(9):971–8.

Riesenberg H, Müller F, Gömmer M. Leukemoid reaction in a patient with adenocarcinoma of the lung: a case report. J Med Case Rep. 2012;6(1):211.

Shalom G, Sion-Vardy N, Dudnik J, Ariad S. Leukemoid reaction in lung cancer possibly caused by anti-NY-ESO-1 immunity. Lung cancer (Amsterdam, Netherlands) 2009, 65(1):119–122.

Norling LV, Serhan CN. Profiling in resolving inflammatory exudates identifies novel anti-inflammatory and pro-resolving mediators and signals for termination. J Intern Med. 2010;268(1):15–24.

Zhang Q, Zhu B, Li Y. Resolution of Cancer-promoting inflammation: a new approach for anticancer therapy. Front Immunol. 2017;8:271.

Ramon S, Bancos S, Serhan CN, Phipps RP. Lipoxin a(4) modulates adaptive immunity by decreasing memory B-cell responses via an ALX/FPR2-dependent mechanism. Eur J Immunol. 2014;44(2):357–69.

Chircuča V, Leutl A, Dull J, Jacobsson A, Battistini L, Maccarrone M, Serhan CN. Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses. Science translational medicine 2016, 8(353):353ra111.

Li B, Huang X, Fu L. Impact of smoking on efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer patients: a meta-analysis. OncoTargets and Therapy. 2018;11:3691–6.

Yu H, Boyle TA, Zhou C, Rimm DL, Hirsch FR. PD-L1 expression in lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016;11(7):964–75.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions